Genetically engineered bacteriocins and their potential as the next generation of antimicrobials

Current Pharmaceutical Design

Volumn 11, Issue 8, 2005, Pages 1067-1075

  Gillor, Osnat ^a,b   Nigro, Lisa M ^a   Riley, Margaret A ^a  

^a YALE UNIVERSITY   (United States)

^b Osborn Memorial Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCOVENIN; ANTIBIOTIC AGENT; BACTERIOCIN; COLICIN; COLICIN E1; DESIGNER DRUG; DURAMYCIN; EPIDERMIN; GALLIDERMIN; LANTHIOPEPTIN; LANTIBIOTIC; MERSACIDIN; METICILLIN; MICROCIN B17; NISIN; PENICILLIN G; PYOCIN; VANCOMYCIN;

ALLERGY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACILLUS SUBTILIS; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CITROBACTER FREUNDII; DENTAL CARIES; DNA MODIFICATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENTEROBACTER CLOACAE; ENTEROCOCCUS GALLINARUM; ESCHERICHIA COLI; GENETIC ENGINEERING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HAFNIA ALVEI; HELICOBACTER PYLORI; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HYPERTENSION; INFECTION CONTROL; INFLAMMATION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; LUNG INFECTION; MASTITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEISSERIA; NONHUMAN; PECTOBACTERIUM CAROTOVORUM; PEPTIC ULCER; PLANT DISEASE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA; SALMONELLOSIS; SERRATIA PLYMUTHICA; SKIN INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOMYCES; STREPTOVERTICILLIUM; XANTHOMONAS CAMPESTRIS;

ANIMALS; BACTERIA; BACTERIOCINS; HUMANS; PROTEIN ENGINEERING;

EID: 14744300441     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381666     Document Type: Review

References (119)

1. Bennett JW, Chung KT. Alexander Fleming and the discovery of penicillin. Adv Appl Microbiol 2001; 49: 163-84.
2. Dowell SF, Kupronis BA, Zell ER, Shay DK. Mortality from pneumonia in children in the United States, 1939 through 1996. N Engl J Med 2000; 342: 1399-407.
3. Knowles DJC. New strategies for antibacterial drug design. Trends Microbiol 1997; 5: 379-83.
4. Levin BR, Antia R, Berliner E, Bloland P, Bonhoeffer S, Cohen M, et al. Resistance to antimicrobial chemotherapy: A prescription for research and action. Am J Med Sci 1998; 315: 87-94.
5. World Health Organization; Press Release WHO/41.http://www.who.int 2000.
6. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11: 757-65.
7. van Houten MA, Luinge K, Laseur M, Kimpen JL. Antibiotic utilisation for hospitalised paediatric patients. Int J Antimicrob Agents 1998; 10: 161-4.
8. Wester CW, Durairaj L, Evans AT, Schwartz DN, Husain S, Martinez E. Antibiotic resistance - A survey of physician perceptions. Arch Intern Med 2002; 162: 2210-6.
9. Solomon DH, Van Houten L, Glynn RJ, Baden L, Curtis K, Schrager H, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001; 161: 1897-902.
10. van den Bogaard AE, Stobberingh EE. Antibiotic usage in animals - Impact on bacterial resistance and public health. Drugs 1999; 58: 589-607.
11. Barton MD, Hart WS. Public health risks: Antibiotic resistance - Review. Asian-Australasian J Animal Sci 2001; 14: 414-22.
12. McManus PS, Stockwell VO, Sundin GW, Jones AL. Antibiotic use in plant agriculture. Annu Rev Phytopathol 2002; 40: 443-65.
13. Sherley M, Gordon DM, Collignon PJ. Variations in antibiotic resistance profile in Enterobacteriaceae isolated from wild Australian mammals. Environ Microbiol 2000; 2: 620-31.
14. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Infect 1998; 36: 5-15.
15. Verschuere L, Rombaut G, Sorgeloos P, Verstraete W. Probiotic bacteria as biological control agents in aquaculture. Microbiol Mol Biol Rev 2000; 64: 655-71.
16. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002; 15: 501-6.
17. Joerger RD. Alternatives to antibiotics: Bacteriocins, antimicrobial peptides and bacteriophages. Poult Sci 2003; 82: 640-7.
18. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 465-99.
19. Pag U, Sahl HG. Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr Pharm Des 2002; 8: 815-33.
20. Twomey D, Ross RP, Ryan M, Meaney B, Hill C. Lantibiotics produced by lactic acid bacteria: structure, function and applications. Antonie Van Leeuwenhoek 2002; 82: 165-85.
21. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol 2003; 21: 556-62.
22. Lazdunski CJ, Bouveret E, Rigal A, Journet L, Lloubes R, Benedetti H. Colicin import into Escherichia coli cells. J Bacteriol 1998; 180: 4993-5002.
23. Gratia A. Sur un remarquable exemple d'antagonisme entre deux souches de coilbacille. Comp Rend Soc Biol 1925; 93: 1040-1.
24. Riley MA, Wertz JE. Bacteriocins: evolution, ecology, and application. Annu Rev Microbiol 2002; 56: 117-37.
25. Smarda J, Smajs D. Colicins--exocellular lethal proteins of Escherichia coli. Folia Microbiol (Praha) 1998; 43: 563-82.
26. Braun V, Pilsl H, Gross P. Colicins: structures, modes of action, transfer through membranes, and evolution. Arch Microbiol 1994; 161: 199-206.
27. van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP. Lantibiotics: biosynthesis, mode of action and applications. Nat Prod Rep 1999; 16: 575-87.
28. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 1993; 12: 39-85.
29. Nes IF, Diep DB, Havarstein LS, Brurberg MB, Eijsink V, Holo H. Biosynthesis of bacteriocins in lactic acid bacteria. Antonie Van Leeuwenhoek 1996; 70: 113-28.
30. Garneau S, Martin NI, Vederas JC. Two-peptide bacteriocins produced by lactic acid bacteria. Biochimie 2002; 84: 577-92.
31. Sahl HG, Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu Rev Microbiol 1998; 52: 41-79.
32. Sahl HG, Jack RW, Bierbaum G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem 1995; 230: 827-53.
33. Guder A, Wiedemann I, Sahl HG. Posttranslationally modified bacteriocins--the lantibiotics. Biopolymers 2000; 55: 62-73.
34. Kuipers OP, Beerthuyzen MM, de Ruyter PG, Luesink EJ, de Vos WM. Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J Biol Chem 1995; 270: 27299-304.
35. Quadri LE. Regulation of antimicrobial peptide production by autoinducer-mediated quorum sensing in lactic acid bacteria. Antonie Van Leeuwenhoek 2002; 82: 133-45.
36. Riley MA, Goldstone CM, Wertz JE, Gordon D. A phylogenetic approach to assessing the targets of microbial warfare. J Evol Biol 2003; 16: 690-7.
37. Riley MA, Gordon DM. A survey of Col plasmids in natural isolates of Escherichia coli and an investigation into the stability of Col-plasmid lineages. J Gen Microbiol 1992; 138: 1345-52.
38. Riley MA, Pinou T, Wertz JE, Tan Y, Valletta CM. Molecular characterization of the klebicin B plasmid of Klebsiella pneumoniae Plasmid 2001; 45: 209-21.
39. Wertz JE, Riley MA. Chimeric nature of two plasmids of Hafnia alvei encoding the bacteriocins alveicins A and B. J Bacteriol 2004; 186: 1598-605.
40. Riley MA, Gordon DM. The ecological role of bacteriocins in bacterial competition. Trends Microbiol 1999; 7: 129-33.
41. Lakey JH, Slatin SL. Pore-forming colicins and their relatives. Curr Top Microbiol Immunol 2001; 257: 131-61.
42. Pons AM, Lanneluc I, Cottenceau G, Sable S. New developments in non-post translationally modified microcins. Biochimie 2002; 84: 531-7.
43. Moreno F, Gonzalez-Pastor JE, Baquero MR, Bravo D. The regulation of microcin B, C and J operons. Biochimie 2002; 84: 521-9.
44. Moreno F, San Millan JL, Hernandez-Chico C, Kolter R. Microcins. Biotechnology 1995; 28: 307-21.
45. Destoumieux-Garzon D, Peduzzi J, Rebuffat S. Focus on modified microcins: structural features and mechanisms of action. Biochimie 2002; 84: 511-9.
46. Gaillard-Gendron S, D. V, Cottenceau G, Graber M, Zorn N, van Dorsselaer A, Pons AM. Isolation, purification and partial amino acid sequence of a highly hydrophobic new microcin named microcin L produced by Escherichia coli. FEMS Microbiol Lett 2000; 193: 95-8.
47. Michel-Briand Y, Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie 2002; 84: 499-510.
48. Nakayama K, Takashima K, Ishihara H, Shinomiya T, Kageyama M, Kanaya S, Ohnishi M, Murata T, Mori H, Hayashi T. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol Microbiol 2000; 38: 213-31.
49. Higerd TB, Baechler CA, Berk RS. In vitro and in vivo characterization of pyocin. J Bacteriol 1967; 93: 1976-86.
50. Kageyama M. Studies of a Pyocin. I. Physical and Chemical Properties. J Biochem (Tokyo) 1964; 55: 49-53.
51. Kuroda K, Kagiyama R. Biochemical relationship among three F-type pyocins, pyocin F1, F2, and F3, and phage KF1. J Biochem (Tokyo) 1983; 94: 1429-41.
52. Takeya K, Minamishima Y, Amako K, Ohnishi Y. A small rod-shaped pyocin. Virology 1967; 31: 166-8.
53. Parret A, De Mot R. Novel bacteriocins with predicted tRNase and pore-forming activities in Pseudomonas aeruginosa PAO1. Mol Microbiol 2000; 35: 472-3.
54. Duport C, Baysse C, Michel-Briand Y. Molecular characterization of pyocin S3, a novel S-type pyocin from Pseudomonas aeruginosa. J Biol Chem 1995; 270: 8920-7.
55. Parret AH, De Mot R. Bacteria killing their own kind: novel bacteriocins of Pseudomonas and other gamma-proteobacteria. Trends Microbiol 2002; 10: 107-12.
56. Filiatrault MJ, Munson RS, Campagnari AA. Genetic analysis of a pyocin-resistant lipooligosaccharide (LOS) mutant of Haemophilus ducreyi: restoration of full-length LOS restores pyocin sensitivity. J Bacteriol 2001; 183: 5756-61.
57. Andersen SR, Bjune G, Lyngby J, Bryn K, Jantzen E. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb Pathog 1995; 19: 159-68.
58. Jabrane A, Sabri A, Compere P, Jacques P, Vandenberghe I, Van Beeumen J, Thonart P. Characterization of serracin P, a phage-tail-like bacteriocin, and its activity against Erwinia amylovora, the fire blight pathogen. App Environ Microbiol 2002; 68: 5704-10.
59. Nguyen HA, Tomita T, Hirota M, Kaneko J, Hayashi T, Kamio Y. DNA inversion in the tail fiber gene alters the host range specificity of carotovoricin Er, a phage-tail-like bacteriocin of phytopathogenic Erwinia carotovora subsp. carotovora Er. J Bacteriol 2001; 183: 6274-81.
60. Fett WF, Maher GT. Bacteriocin production by Xanthomonas-campestris pv glycines. Phytopathology 1985; 75: 1280-.
61. Heu S, Oh J, Kang Y, Ryu S, Cho SK, Cho Y, Cho M. gly gene cloning and expression and purification of glycinecin A, a bacteriocin produced by Xanthomonas campestris pv. glycines 8ra. Appl Environ Microbiol 2001; 67: 4105-10.
62. Montville TJ, Winkowski K. In Food Microbiology: Fundamentals and Frontiers, M. P. Doyle; L. R. Beuchat; T. J. Montville, eds.; American Society for Microbiology Press: Washington, D.C., 1997, pp. 559.
63. Cleveland J, Montville TJ, Nes IF, Chikindas ML. Bacteriocins: safe, natural antimicrobials for food preservation. Int J Food Microbiol 2001; 71: 1-20.
64. Bower CK, Bothwell MK, McGuire J. Lantibiotics as surface active agents for biomedical applications. Colloids and Surfaces B: Biointerfaces 2001; 22.
65. Post RC. Regulatory perspective of the USDA on the use of antimicrobials and inhibitors in foods. J Food Prot 1996; :78-81 Suppl. S.
66. Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 1996; 69: 193-202.
67. Severina E, Severin A, Tomasz A. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother 1998; 41: 341-7.
68. Bower CK, Parker JE, Higggins AZ, Oest ME, Wilson JT, Valentin BA, et al. Protein antimicrobial barrier to bacterial adhesion: in vitro and in vivo evaluaution of nisin-treated implamentable materials. Colloids and Surfaces B: Biointerfaces 2002; 25: 81-90.
69. Allgaier H, Jung G, Werner RG, Schneider U, Zahner H. Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. Eur J Biochem 1986; 160: 9-22.
70. Kellner R, Jung G, Horner T, Zahner H, Schnell N, Entian KD, Gotz F. Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur J Biochem 1988; 177: 53-9.
71. Naruse N, Tenmyo O, Tomita K, Konishi M, Miyaki T, Kawaguchi H, Fukase K, Wakamiya T, Shiba T. Lanthiopeptin, a new peptide antibiotic. Production, isolation and properties of lanthiopeptin. J Antibiot (Tokyo) 1989; 42: 837-45.
72. Bierbaum G, Brotz H, Koller KP, Sahl HG. Cloning, sequencing and production of the lantibiotic mersacidin. FEMS Microbiol Lett 1995; 127: 121-6.
73. Kido Y, Hamakado T, Yoshida T, Anno M, Motoki Y, Wakamiya T, Shiba T. Isolation and characterization of ancovenin, a new inhibitor of angiotensin I converting enzyme, produced by actinomycetes. J Antibiot (Tokyo) 1983; 36: 1295-9.
74. Marki F, Hanni E, Fredenhagen A, van Oostrum J. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol 1991; 42: 2027-35.
75. Ryan MP, Meaney WJ, Ross RP, Hill C. Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol 1998; 64: 2287-90.
76. Ryan MP, Flynn J, Hill C, Ross RP, Meaney WJ. The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental challenge with Streptococcus dysgalactiae in nonlactating dairy cows. J Dairy Sci 1999; 82: 2625-31.
77. Jordi BJ, Boutaga K, van Heeswijk CM, van Knapen F, Lipman LJ. Sensitivity of Shiga toxin-producing Escherichia coli (STEC) strains for colicins under different experimental conditions. FEMS Microbiol Lett 2001; 204: 329-34.
78. Sable S, Pons AM, Gendron-Gaillard S, Cottenceau G. Antibacterial activity evaluation of microcin J25 against diarrheagenic Escherichia coli. Appl Environ Microbiol 2000; 66: 4595-7.
79. Wooley RE, Gibbs PS, Shotts EB. Inhibition of Salmonella typhimurium in the chicken intestinal tract by a transformed avirulent avian Escherichia coli. Avian Dis 1999; 43: 245-50.
80. Phillips CA. The epidemiology, detection and control of Escherichia coli O157. J Sci Food Agric 1999; 79: 1367-81.
81. Stevens MP, van Diemen PM, Dziva F, Jones PW, Wallis T. Options for the control of enterohaemorrhagic Escherichia coli in ruminants. Microbiol Mol Biol Rev 2002; 148: 3767-78.
82. Zhao T, Doyle MP, Harmon BG, Brown CA, Mueller PO, Parks AH. Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria. J Clin Microbiol 1998; 36: 641-7.
83. Doyle MP, Zhao T, Harmon BG, Brown CA. Control of enterohemorrhagic E. coli O157:H7 in cattle by probiotic bacteria and specific strains of E. coli. University of Georgia Research Foundation Inc. (Athens, GA), USA 1999. 5965128.
84. Yorgey P, Lee J, Kordel J, Vivas E, Warner P, Jebaratnam D, Kolter R. Posttranslational modifications in microcin B17 define an additional class of DNA gyrase inhibitor. Proc Natl Acad Sci USA 1994; 91: 4519-23.
85. Portrait V, Gendron-Gaillard S, Cottenceau G, Pons AM. Inhibition of pathogenic Salmonella enteritidis growth mediated by Escherichia coli microcin J25 producing strains. Can J Microbiol 1999; 45: 988-94.
86. Pons AM, Delalande F, Duarte M, Benoit S, Lanneluc I, Sable S, Van Dorsselaer A, Cottenceau G. Genetic analysis and complete primary structure of microcin L. Antimicrob Agents Chemother 2004; 48: 505-13.
87. Coburn PS, Gilmore MS. The Enterococcus Faecalis cytolysin: a novel toxin active against eukaryotic and prokaryotic cells. Cell Microbiology 2003; 5: 661-9.
88. Lazebnik Y. Why do regulators of apoptosis look like bacterial toxins? Curr Biol 2001; 11: R767-8.
89. Hetz C, Bono MR, Barros LF, Lagos R. Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci USA 2002; 99: 2696-701.
90. Walker DC, Georgiou T, Pommer AJ, Walker D, Moore GR, Kleanthous C, James R. Mutagenic scan of the H-N-H motif of colicin E9: implications for the mechanistic enzymology of colicins, homing enzymes and apoptotic endonucleases. Nucleic Acids Res 2002; 30: 3225-34.
91. McManus PS, Stockwell VO, Sundin GW, Jones AL. Antibiotic use in plant agriculture. Ann Rev Phytopathol 2002; 40: 443-65.
92. Cook RJ. Making greater use of introduced microorganisms for biological control of plant pathogens. Annn Rev Phytopathol 1993; 31: 53-80.
93. Chen WY, Echandi E. Effects of avirulent bacteriocin-producing strains of Pseudomonas-solanacearum on the control of bacterial wilt of tobacco. Plant Pathology 1984; 33: 245-53.
94. Sakthivel N, Mew TW. Efficacy of bacteriocinogenic strains of Xanthomonas-oryzae pv oryzae on the incidence of bacterial-blight disease of rice (Oryza-sativa 1). Can J Microbiol 1991; 37: 764-8.
95. Lavermicocca P, Lonigro SL, Valerio F, Evidente A, Visconti A. Reduction of olive knot disease by a bacteriocin from Pseudomonas syringae pv. ciccaronei. Appl Environ Microbiol 2002; 68: 1403-7.
96. Rodriguez JM, Martinez MI, Horn N, Dodd HM. Heterologous production of bacteriocins by lactic acid bacteria. Int J Food Microbiol 2003; 80: 101-16.
97. Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev 1996; 60: 512-38.
98. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-33.
99. Mayville PGJ, Beavis R, Yang H, Goger M, Novick RP, Muir TW. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci USA 1999; 96: 1218-23.
100. Ji G, Beavis RC, Novick R, P. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci USA 1995; 92: 12055-9.
101. Qiu XQ, Wang H, Lu XF, Zhang J, Li SF, Cheng G, Wan L, Yang L, Zuo JY, Zhou YQ, Wang HY, Cheng X, Zhang SH, Ou ZR, Zhong ZC, Cheng JQ, Li YP, Wu GY. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat Biotechnol 2003; 21: 1480-5.
102. Hillman JD. Replacement therapy of dental caries. Oper Dent Suppl 2001; 6: 39-40.
103. van Belkum MJ, Worobo RW, Stiles ME. Double-glycine-type leader peptides direct secretion of bacteriocins by ABC transporters: colicin V secretion in Lactococcus lactis. Mol Microbiol 1997; 23: 1293-301.
104. Kim Y, Cho SK, Cho M. Improvemen in the stability of glycinecin A through protein fusion of the two structural components. J Microbiol 2001; 39: 177-80.
105. Breukink E, de Kruijff B. The lantibiotic nisin, a special case or not? Biochim Biophys Acta 1999; 1462: 223-34.
106. Cortes-Perez NG, Bermudez-Humaran LG, Le Loir Y, Rodriguez-Padilla C, Gruss A, Saucedo-Cardenas O, Langella P, Montes-de-Oca-Luna R. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003; 229: 37-42.
107. Portrait V, Gendron-Gaillard S, Cottenceau G, Pons AM. Inhibition of pathogenic Salmonella enteritidis growth mediated by Escherichia coli microcin J25 producing strains. Can J Microbiol 1999; 45: 988-94.
108. Wooley RE, Shouts EB. Biological control of food pathogens in livestock. University of Georgia Research Foundation, Inc. (Athens, GA), USA 2000. 5043176.
109. van der Hoeven JS, Rogers AH. Stability of the resident microflora and the bacteriocinogeny of Streptococcus mutans as factors affecting its establishment in specific pathogen-free rats. Infect Immun 1979; 23: 206-13.
110. Beighton D, Hayday H, Walker J. The acquisition of Streptococcus mutans by infant monkeys (Macaca fascicularis) and its relationship to the initiation of dental caries. J Gen Microbiol 1982; 128 (Pt 8): 1881-92.
111. Hillman JD. Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie Van Leeuwenhoek 2002; 82: 361-6.
112. Hillman JD. Novel antimicrobial polypeptides and methods of use. University of Florida Research Foundation, Inc., United States of America 2002.
113. Hillman JD. Antimicrobial polypetides, nucleic acid, and methods of use. University of Florida, United States of America 2002.
114. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun 2000; 68: 543-9.
115. Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995; 61: 2873-8.
116. Takahara Y, Iwabuchi T, Shiota M. Method for controlling soft rot, bacterial seedling blights of rice and black rot. Central Glass Co., Ltd. (Ube, JP), USA 1995. 5441735.
117. Lee KH. Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. Curr Pharm Design 2002; 8(9): 795-813.
118. Pag U, Sahl HG. Multiple activities in lantibiotics--models for the design of novel antibiotics? Curr Pharm Design 2002; 8(9): 815-33.
119. Shafer WM, Katzif S, Bowers S, Fallon M, Hubalek M, Reed MS, el al. Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogens. Curr Pharm Design 2002; 8(9): 695-702.